Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
Biomarkers, Tumor
/ analysis
DNA Mismatch Repair
DNA Repair Enzymes
/ analysis
Digestive System Neoplasms
/ enzymology
Endometrial Neoplasms
/ enzymology
Female
Genital Neoplasms, Female
/ enzymology
Humans
Immunohistochemistry
Italy
Male
Microfluidic Analytical Techniques
Microsatellite Instability
Molecular Diagnostic Techniques
Ovarian Neoplasms
/ enzymology
Pancreatic Neoplasms
/ enzymology
Polymerase Chain Reaction
Predictive Value of Tests
Prostatic Neoplasms
/ enzymology
Reproducibility of Results
Retrospective Studies
Stomach Neoplasms
/ enzymology
IHC
MMR
MSI
fully automated RT-PCR
immune checkpoint inhibitors (ICIs)
immunotherapy
microfluidic
predictive molecular pathology
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 07 2021
24 07 2021
Historique:
received:
25
05
2021
revised:
21
07
2021
accepted:
22
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Immune-checkpoint inhibitors (ICIs) play a key role in the treatment of advanced stage colorectal cancer (CRC) patients featuring a deficient DNA mismatch repair (dMMR) system or a high microsatellite instability (MSI-H) profile. However, beyond the established role in CRC patients, ICIs have highly proven efficacy in other solid tumors featuring MSI-H/dMMR status represented by endometrial, gastric, ovarian, prostatic, and pancreatic carcinomas (EC, GC, OC, PrC, and PaC). Our aim was to compare the concordance rates among the Idylla™ MSI test, TapeStation 4200, and immunohistochemical (IHC) analysis in assessing MSI-H/dMMR status in EC, GC, OC, PrC, and PaC patients. The Sanger sequencing-based Titano MSI test was used in discordant cases. One hundred and eighty-five cases (
Identifiants
pubmed: 34440647
pii: cells10081878
doi: 10.3390/cells10081878
pmc: PMC8391221
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA Repair Enzymes
EC 6.5.1.-
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Monitoraggio ambientale, studio ed approfondimento della salute della popolazione residente in aree a rischio
ID : In attuazione della D.G.R. Campania n.180/2019
Organisme : Progetto "Sviluppo di Approcci Terapeutici Innovativi per patologie Neoplastiche resistenti ai trattamenti-SATIN"
ID : POR Campania FESR 2014-2020
Organisme : Italian Health Ministry and Veneto Region research program
ID : NET-2016-02363853
Références
Cancer Med. 2021 Jan;10(1):53-61
pubmed: 33314633
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
J Clin Pathol. 2017 Jan;70(1):90-91
pubmed: 27872139
Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a012633
pubmed: 23545421
PLoS One. 2010 Feb 24;5(2):e9393
pubmed: 20195377
Gastroenterology. 2018 Mar;154(4):1061-1065
pubmed: 29158190
Genes (Basel). 2020 Dec 29;12(1):
pubmed: 33383713
Sci Rep. 2020 Oct 2;10(1):16386
pubmed: 33009475
J Mol Diagn. 2020 Mar;22(3):386-395
pubmed: 31881332
Cells. 2020 Sep 02;9(9):
pubmed: 32887373
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Virchows Arch. 2021 May;478(5):851-863
pubmed: 33170334
J Clin Pathol. 2019 Dec;72(12):830-835
pubmed: 31235541
Arch Pathol Lab Med. 2019 Oct;143(10):1225-1233
pubmed: 30917047
J Pathol Transl Med. 2019 Nov;53(6):386-392
pubmed: 31606978
Histopathology. 2021 Mar;78(4):485-497
pubmed: 33010064
J Clin Pathol. 2021 Jan;74(1):36-42
pubmed: 32513848
Cancer Cell Int. 2020 Jan 13;20:16
pubmed: 31956294
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618962
Int J Mol Sci. 2019 Oct 16;20(20):
pubmed: 31623180
Oncoimmunology. 2019 Mar 5;8(5):e1581547
pubmed: 31069144
Pharmacol Ther. 2018 Sep;189:45-62
pubmed: 29669262
Am J Surg Pathol. 2010 Dec;34(12):1798-804
pubmed: 21107085
Clin Cancer Res. 2008 Nov 1;14(21):6847-54
pubmed: 18980979
J Clin Pathol. 2009 Sep;62(9):850-2
pubmed: 18641409
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Oncol. 2017 Jan 1;28(1):96-102
pubmed: 27742654
Biomed Res Int. 2019 Apr 24;2019:9056417
pubmed: 31179334
J Clin Pathol. 2020 Nov;73(11):741-747
pubmed: 32273401
Mod Pathol. 2021 May;34(5):1031-1032
pubmed: 32980858
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530449
JAMA. 2012 Oct 17;308(15):1555-65
pubmed: 23073952
Exp Mol Pathol. 2020 Oct;116:104519
pubmed: 32822722
Clin Cancer Res. 2017 Sep 1;23(17):5246-5254
pubmed: 28522602
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-7
pubmed: 32213091
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
JAMA Oncol. 2019 Apr 1;5(4):471-478
pubmed: 30589920
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182707
Clin Colorectal Cancer. 2019 Dec;18(4):e316-e323
pubmed: 31375292
Eur J Hum Genet. 2008 Jul;16(7):804-11
pubmed: 18301449
Pathologica. 2020 Sep;112(3):248-259
pubmed: 33179625
J Clin Pathol. 2021 Sep;74(9):604-607
pubmed: 33020177
Virchows Arch. 2021 Mar 23;:
pubmed: 33755781
J Pathol Clin Res. 2019 Apr;5(2):115-129
pubmed: 30387329
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Mod Pathol. 2019 May;32(5):650-658
pubmed: 30443012
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809329